18 F]FDDNP PET scanning may have practical utility in identifying people at risk for future cognitive decline and in tracking the effectiveness of novel interventions designed to prevent or delay neurodegeneration and cognitive decline.
F]FDDNP positron emission tomography (PET) binding values in the medial and lateral temporal, posterior cingulate, parietal, frontal, and global (mean) regions of interest; neuropsychological test battery measuring 5 cognitive domains, including memory, language, attention (and information-processing speed), executive functioning, and visuospatial ability.
Results: For the entire study group (MCI and normal aging), increases in frontal, posterior cingulate, and global binding at follow-up correlated with progression of memory decline (r=−0.32 to −0.37, P=.03 to .01) after 2 years. Moreover, higher baseline [ 18 F]FDDNP binding was associated with future decline in most cognitive domains, including language, attention, executive, and visuospatial abilities (r=−0.31 to −0.56, P=.05 to .002). For the MCI group, frontal and parietal [ 18 F]FDDNP binding yielded the greatest diagnostic accuracy in identifying converters to Alzheimer disease vs nonconverters after 2 years, with an area under the receiver operating characteristic curve of 0.88 (95% CI, 0.72-1.00) compared with 0.68 (95% CI, 0.45-0.91) for medial temporal binding.
Conclusions: [ 18 F]FDDNP PET regional binding patterns are consistent with known neuropathologic patterns of plaque and tangle brain accumulation, spreading from the medial temporal to other neocortical regions as disease progresses. Because binding patterns predict future cognitive decline and increase over time along with clinical decline, [ 18 F]FDDNP PET scanning may have practical utility in identifying people at risk for future cognitive decline and in tracking the effectiveness of novel interventions designed to prevent or delay neurodegeneration and cognitive decline.
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N EURODEGENERATION AND cognitive losses afflict millions of people as they age. Nearly 20% of people 65 years or older have mild cognitive impairment (MCI), 1 and 10% have dementia.
2,3 Such a high prevalence has led to recent research on the development of brain imaging tools to track the neuropathologic changes associated with these conditions. Since the initial positron emission tomography (PET) report 4 demonstrating the feasibility of in vivo imaging of amyloid senile plaques and tau neurofibrillary tangles using 2-(1-{6-[(2-fluorine 18-labeled fluoroethyl) methylamino]-2-napthyl}ethylidene) malononitrile ([ 18 F]FDDNP) in living people, several molecular imaging probes (eg, carbon 11-Pittsburgh Compound B and fluorine 18-labeled florbetapir [5] [6] [7] [8] ) have been developed to image amyloid in patients with Alzheimer disease (AD) and MCI. Although carbon 11-Pittsburgh Compound B and fluorine 18-labeled florbetapir [5] [6] [7] [8] measure only amyloid and show relatively higher cortical signals than does [ 18 F]FDDNP in patients with AD compared with controls, [ 18 F]FDDNP is the only molecular PET probe that provides a measure of both amyloid and tau. 9, 10 Previous cross-sectional studies [9] [10] [11] 
METHODS

STUDY PARTICIPANTS AND CLINICAL ASSESSMENTS
We performed baseline and follow-up cognitive and neuroimaging assessments on 43 individuals selected from a pool of 319 potential volunteers. Volunteers were recruited through advertisements regarding mild memory concerns, media coverage, and referrals from physicians and families. For inclusion, volunteers needed to be willing to participate in a longitudinal study on memory and aging. Although all study participants had noticed mild memory changes, those with any form of dementia at baseline assessments were excluded. From the original pool, volunteers were excluded for the following reasons: medical and psychiatric illnesses (n = 131); loss of interest (n = 96); use of medications (n = 38) that might affect cognition (eg, sedatives) or nonsteroidal anti-inflammatory drugs, which bind to amyloid plaques and may affect [ ; and inability to undergo magnetic resonance imaging (MRI) (n=11) because of pacemakers or hip replacement implants.
Participants underwent screening laboratory tests and structural imaging scans (3-dimensional MRI or computed tomography [CT]) to rule out other causes of cognitive impairment (eg, stroke, tumor) 18 and for coregistration with PET scans for region-of-interest image analyses. Computed tomography instead of MRI was performed on 4 individuals because they could not tolerate MRI (eg, owing to claustrophobia or metal in the body). Those with vascular lesions apparent on MRI or CT were also excluded from the study. In addition to the Mini-Mental State Examination 19 and Hamilton Rating Scale for Depression, 20 a neuropsychological test battery 21 was administered to assess 5 cognitive domains: (1) memory, including the Wechsler Memory Scale, third edition, logical memory (delayed score), Buschke Selective Reminding Test (total score), and ReyOsterrieth Complex Figure Recall Figure Copy . To ascertain cognitive change in individuals, for each of the cognitive measures, we first calculated change scores (follow-up minus baseline). These raw change scores were converted to z scores by standardizing them to a mean of 0 and an SD of 1. A domain z score was obtained by averaging those z scores belonging to the cognitive tests in that domain. The domain z scores were used to examine associations with [ 18 F]FDDNP brain regional binding levels. We used standard diagnostic criteria for amnestic MCI (ie, memory impairment without other cognitive impairments), which include (1) patient awareness of a memory problem, preferably confirmed by another person who knows the patient; (2) memory impairment detected with standard assessment tests; and (3) ability to perform normal daily activities. 22 For a broad definition of MCI, we also used guidelines to identify those with other MCI subtypes, including those with memory impairment and additional cognitive deficits. 23 The diagnosis was corroborated by clinical judgment 22 and included patients with MCI who scored 1 SD or more below the age-corrected norms because this threshold for impairment yields high sensitivity for predicting dementia. 24 To balance increased sensitivity with specificity, impairment on at least 2 neuropsychological tests within 1 of the 5 cognitive domains was required. 25 Patients in the MCI group did not meet diagnostic criteria for AD, 18, 26 and the presence of memory concerns was documented using a standardized subjective memory instrument (Memory Functioning Questionnaire) 27 and clinical interview. Volunteers with 1 or more first-degree relatives (ie, sibling or parent) with AD or dementia were classified as having a positive family history of dementia. Prior educational achievement was quantified according to years and months of school completed, beginning with elementary school (ie, first grade).
All clinical assessments were performed within 4 weeks of scanning procedures, and physicians were masked to [ 
SCANNING AND IMAGE ANALYSIS PROCEDURES
As previously described, [ 18 F]FDDNP was prepared at high specific activities (Ͼ37 GBq/µmol). 28 All scans (EXACT HRϩ tomograph; Siemens-CTI) were performed with participants in a supine position and with the imaging plane parallel to the orbitomeatal line. A bolus of [ 18 F]FDDNP (320-550 MBq) was injected via an indwelling venous catheter, and consecutive dynamic PET scans were performed for 1 hour. Scans were decay corrected and reconstructed using filtered backprojection (Hann filter, 5.5 mm full-width at half-maximum) with scatter and measured attenuation correction. The resulting images contained 63 contiguous sections with plane separation of 2.42 mm (EXACT HRϩ).
The [ 18 F]FDDNP binding data were quantified using Logan graphical analysis with the cerebellum as the reference region. 9, 29 The slope of the linear portion of the Logan plot is the relative distribution volume of the tracer in a region of interest divided by that in the reference region. The relative distribution volume parametric images were generated and analyzed using regions of interest traced on the coregistered MRIs for the left and right parietal, medial temporal (limbic regions, including hippocampus, parahippocampal areas, and entorhinal cortex), lateral temporal, posterior cingulate, and frontal regions, as previously described 9 ( Figure 1 ). Each regional relative distribution volume or binding value was expressed as the mean of the left and right regions, and the global region was defined as the mean of these. Rules for region-of-interest drawing were based on the identification of gyral and sulcal landmarks with respect to the atlas of Talairach and Tournoux. 30 All PET scans were read and regions of interest drawn by individuals who were masked to clinical assessments.
STATISTICAL ANALYSIS
Data were screened for outliers and normality assumptions. Descriptive statistics were computed for the entire sample and for the MCI and the normal aging groups separately. The 2-sample Wilcoxon rank sum test was used to compare the continuous variables of cognitive groups and Fisher exact 2 test for categorical variables. Within the MCI and normal aging groups, significance of changes in regional [ 18 F]FDDNP binding levels was examined using the nonparametric signed rank test, and between-group comparisons were made using the nonparametric Wilcoxon 2-sample rank sum test, which also was used to compare the MCI with AD converters vs nonconverters.
To accommodate nonlinear relationships among variables, we used rank-based models to study the associations between [ To assess whether MCI and normal aging groups can be pooled together for these correlations, we performed a bootstrap randomization experiment, which suggested that the 2 groups can be pooled together for correlation estimation.
To examine whether baseline [ 18 F]FDDNP cortical binding levels were associated with cognitive changes at followup, nonparametric analyses of covariance were estimated with the cognitive domain change scores as dependent variables, but using baseline [ balance between sensitivity and specificity. We selected the best cut point as the point on the ROC curve farthest away from the line connecting the lower left-hand and upper right-hand corners (greatest distance of ROC curve from the line of random prediction). 31 Analyses were performed with the SAS statistical software, version 9.2 (SAS Institute, Inc), and StatXact 8 (Cytel). All reported P values were 2-sided.
RESULTS
BASELINE DEMOGRAPHICS
Study participants without dementia (both MCI and normal aging) were middle-aged or older (median age, 64 years; range, 40-87 years) and highly educated (median educational achievement, 16 years; range, 12-24 years). They also showed relatively minimal impairment on cognitive testing (median Mini-Mental State Examination score, 29; range, 24-30). Most of them (72%) had a family history of dementia in at least 1 first-degree relative. Of the 21 participants with MCI, 12 showed memory impairment consistent with amnestic MCI and 9 had amnestic MCI plus deficits in other cognitive areas. The MCI and normal aging groups did not differ significantly according to age, educational achievement, or other demographic characteristics ( Table 1) . The median interval between baseline and follow-up assessments was 2.0 years (range, 1.4-3.2 years). ues in frontal (mean increase, 3.6%; Wilcoxon signed rank statistic [S] = 106.5; P Ͻ .001), parietal (mean increase, 3.1%; S = 86.5; P = .002), posterior cingulate (mean increase, 4.1%; S= 101.5; P Ͻ .001), and global (mean increase, 2.7%; S= 107.5; P Ͻ.001) regions, whereas binding values in the medial temporal region, already at high levels, did not increase significantly during that period. The normal aging group did not show significant increases in any region. (Figure 2) . The interaction term was not significant, indicating that the MCI and normal aging groups did not differ in these associations. We found that 40% of the study participants (12 in the MCI group and 5 in the normal aging group) had increased (Ͼ0. (Figure 4) indicates how baseline frontal and parietal binding is a better predictor of conversion to AD in MCI patients than is medial temporal binding. Figure 5 illustrates an MCI patient with low frontal binding who did not convert to AD after 2 years compared with an MCI patient with higher frontal binding who converted to AD. In the present study, [
18 F]FDDNP cortical binding values followed the expected neuropathologic patterns. 12, 13 The MCI patients who already had high medial temporal binding did not show significant binding increases in this region; thus, medial temporal binding in MCI seems to plateau and remain stable for 2 years, consistent with earlier observations. 9 By contrast, a high proportion of the MCI patients with frontal and parietal binding above the ROC established threshold showed cognitive decline after 2 years, whereas none of the MCI patients below this threshold showed cognitive change. Moreover, the results of the ROC analysis indicated that high baseline [
18 F]FDDNP binding in frontal and parietal regions (corresponding to spread of disease to these regions) is associated with more rapid cognitive decline. Thus, the pattern of [ 18 F]FDDNP binding in MCI, consistent with known disease progression observed at autopsy, may provide useful information for physicians when individual patients are evaluated. 32 Our previous work using clus- 33 Moreover, those with this high frontal and parietal pattern in MCI also show fluorodeoxyglucose F18 PET patterns consistent with an increased risk for AD. 34 Of the 21 individuals with a diagnosis of MCI at baseline, 12 demonstrated memory impairment consistent with amnestic MCI, whereas the other 9 had amnestic MCI plus deficits in other cognitive areas. These MCI subtypes have a high rate of conversion to dementia, 35, 36 which provides a useful model for evaluating the predictive ability of molecular imaging probes to determine disease progression. In our study, 6 of the 21 MCI patients (29%) converted to AD at the 2-year follow-up visit, a proportion consistent with the 10% to 15% expected annual risk of conversion of amnestic MCI subtypes. 37 The finding that MCI patients with high frontal and parietal binding are more likely to convert to AD after 2 years than those with low binding in these regions further supports the potential utility of [ We expect that many of the normal aging individuals in this study will eventually progress to MCI, and those with higher baseline [ 32,38 Our previous autopsy follow-up study 9 of a patient with high medial temporal [ 18 F]FDDNP binding showed both amyloid and tau, with a preponderance of tau tangle deposits in the medial temporal regional.
In the entire study group and the MCI subgroup, baseline medial temporal [
18 F]FDDNP binding values predicted future executive function decline, an observation that could be explained by disruptions in neural circuitry between medial temporal and frontal regions. Other studies of normal aging indicate neural circuitry disconnections between these 2 cortical areas, including lower entorhinal cortical thickness associated with decreased anterior cingulate and medial frontal activation during a memory retrieval task. 39, 40 Thus, our observation that high baseline medial temporal [ dicts executive function decline is consistent with taumediated disruption of neuronal circuits projecting to prefrontal regions that control executive functioning.
A useful neuroimaging biomarker for neurodegeneration would not only provide visualizations of relevant disease pathophysiologic characteristics and predict the course of disease but would also demonstrate correlations with disease progression over time. 10, 41 Finding practical in vivo measures of neurodegeneration for early disease detection and predicting and tracking disease progression are major challenges to the field. Such noninvasive measures of disease progression might assist in testing and monitoring new preventive treatments for protecting neuronal integrity before significant neural damage emerges. 10, [44] [45] [46] The encouraging longitudinal findings with [ 18 F]FDDNP presented in this work will be useful in future clinical trials for successful monitoring of treatments designed to eliminate or prevent the deposition of amyloid or tau or both.
Recent clinical trials of novel treatments have targeted fibrillar amyloid, but efficacy results have been negative, 47 pointing to limitations in treatment strategies based solely on the amyloid hypothesis. Amyloid and tau aggregates are clearly important in vivo diagnostic targets, but tau aggregates are associated with both neuronal and cognitive losses and are better indicators of disease progression. 48, 49 Using an in vivo tau marker for detection and tracking of neurodegenerative diseases is critically important given findings that severity of tau neurofibrillary tangle load, rather than amyloid plaque burden, correlates with rates of tissue loss and neuronal decline. 50, 51 Even if current antitau treatments prove negative, an in vivo marker for tau aggregates constitutes a useful method to track disease progression at its earlier stages. 51 Thus far, [ 18 F]FDDNP is the only available imaging probe that provides in vivo measures of tau in humans. 9, 10 As in all imaging studies, methodologic limitations should be considered for appropriate interpretation of results. Important considerations include partial volume effects, 14 errors introduced from head motion during scanning (particularly with patients with dementia), 52 and study population selection (eg, educated samples that may not represent the general population). Our MCI sample was relatively younger than other samples reported in the literature, which might reflect our recruitment focus on normal aging rather than populations with dementia. We have found that head motion error is more likely in more severe forms of cognitive impairment observed in patients with dementia, and this can be corrected effectively. 52 Also, the accuracy of cutoffs in the ROC analyses were maximized for this data set, so results from other populations might differ. It is important to crossvalidate these results in a larger sample. In addition, we have used combined left and right regions in our analyses. Future studies will examine the contribution of the left and right regions separately.
Our findings indicate that in vivo regional [
18 F]FDDNP binding patterns are consistent with known patterns of disease deposition and associated with future disease course. Using [
18 F]FDDNP PET may not only assist in predicting future cognitive decline and identifying individuals more likely to benefit from prevention treatments, but it may also track the effectiveness of such treatments to accelerate drug discovery efforts.
